8-K: Revvity Exceeds EPS Guidance, Forecasts Strong 2025 Close

Revvity, Inc. announced preliminary Q4 and full-year 2025 financial results, expecting to exceed adjusted EPS guidance and reporting solid revenue growth.

Summary

• Revvity will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026.
• A conference call will be hosted on February 2, 2026, at 8:00 a.m. ET by President and CEO Prahlad Singh and CFO Max Krakowiak to discuss these results.
• Preliminary fourth quarter 2025 reported revenue growth is expected to be approximately 6%, with organic revenue growth of approximately 4%, resulting in approximately $772 million in revenue.
• For the full year 2025, reported revenue growth is expected to be approximately 4%, with organic revenue growth of approximately 3%, resulting in approximately $2,855 million in revenue.
• Full year adjusted earnings per share are now expected to exceed the upper-end of the previously provided guidance of $4.90-$5.00.
• Prahlad Singh will present at the 44th annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT.
• Revvity provides health science solutions, technologies, expertise, and services, with specialized focus areas in translational multi-omics, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics.
• The company's portfolio is approximately 50% Life Sciences and 50% Diagnostics, with about 85% recurring revenue.
• Operational improvements include a ~10% overall headcount reduction, supply chain optimization, and footprint consolidation impacting over 30 rooftops, expected to deliver ~20% annual cost reductions and ~10% footprint reduction by 2027.
• Revvity has repurchased approximately $1.4 billion in shares since becoming Revvity in 2023, leading to a ~10% reduction in share count.
• The company is on track to achieve 28.0% adjusted operating margins in 2026.
• Long-range plan (LRP) organic growth is targeted at 6-8%, with specific segment growth rates: Life Sciences Solutions (10-12%), Immunodiagnostics (10-12%), Signals Software (4-6%), and Reproductive Health (4-6%).
• Future gross margin expansion is targeted from approximately 27% (2025E) to the mid-30s%.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with preliminary financial results exceeding expectations, robust growth targets, and clear strategic initiatives in high-growth areas like AI and specialized diagnostics. Operational improvements and capital allocation further enhance the positive sentiment.

Positives

• Full year adjusted EPS is expected to exceed the upper-end of the $4.90-$5.00 guidance, indicating stronger-than-expected profitability.
• Preliminary Q4 2025 reported revenue growth of ~6% and organic revenue growth of ~4% demonstrate solid performance.
• Preliminary full year 2025 reported revenue growth of ~4% and organic revenue growth of ~3% reflect consistent top-line expansion.
• A high recurring revenue mix of approximately 85% provides business stability and predictability.
• Significant operational improvements are underway, including a ~10% overall headcount reduction, supply chain optimization, and footprint consolidation, expected to yield ~20% annual cost reductions and ~10% footprint reduction by 2027.
• Strong free cash flow conversion, exceeding 85% of adjusted net income, highlights efficient cash generation.
• Active capital allocation strategy includes ~$1.4 billion in share repurchases since 2023, resulting in a ~10% reduction in share count.
• The company is on track to achieve 28.0% adjusted operating margins in 2026, indicating improved profitability.
• Long-range plan targets 6-8% organic growth, positioned 200bps above market in normal conditions, suggesting strong competitive positioning.
• Expected future gross margin expansion from ~27% (2025E) to mid-30s% signals enhanced profitability potential.
• Strategic focus on AI includes customer-facing solutions like Transcribe AI and internal efficiencies, such as ~10% reduction in software development timelines and ~40% improvement in workflow speed.
• Partnership with Eli Lilly for AI-enabled drug discovery via Signals Xynthetica positions the company at the forefront of innovation.
• Expansion in GMP Reagents with ~2.5x increase in bioprocessing projects in the last 12 months.
• Increasing US Immunodiagnostics penetration, targeting ~40% of total IDx revenue in the future from ~20% in 2025.
• Advancing early detection of Type 1 Diabetes (T1D) globally, including supporting Italy's mandate for early pediatric T1D screening.

Risks

• The preliminary financial results are subject to the completion of quarterly and year-end closing procedures for the fourth quarter and fiscal year ended December 28, 2025.
• Actual results could differ materially from forward-looking statements due to important risk factors described in the company's most recent quarterly report on Form 10-Q and other SEC filings.
• Non-GAAP financial measures cannot be reconciled to GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting excluded items, which could be material to GAAP results.

Future Outlook

Revvity expects existing end market trends to continue into 2026, targeting 2-3% organic growth leading to high-single-digit adjusted EPS growth. The company is on track to achieve 28.0% adjusted operating margins in 2026 and aims for 6-8% long-range organic growth, with future gross margins in the mid-30s%. Strategic initiatives in AI, GMP reagents, and immunodiagnostics are expected to drive continued growth and operational efficiency.

Management Comments

• Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
• Management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items.
• Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance.
• Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures.
• Management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
• Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.
• Expect existing end market trends to continue into 2026.
• On track to achieve 28.0% Adj. Operating Margins.
• 2-3% organic growth expected to result in HSD adj. EPS growth.
• Reiterating our long-term growth algorithm and achieving top-tier margins while delivering DD adj. EPS growth over the long term, with capital deployment providing additional upside.

Industry Context

Revvity operates in the dynamic health science solutions market, encompassing life sciences and diagnostics. The company's strategic focus on AI-driven discovery, expansion in GMP reagents, and penetration in immunodiagnostics aligns with broader industry trends towards technological innovation, personalized medicine, and enhanced diagnostic capabilities. Its partnership with Eli Lilly for AI models-as-a-service positions it at the forefront of leveraging artificial intelligence for drug discovery, a key area of investment across the pharmaceutical and biotech sectors. The company's operational efficiency initiatives, including headcount rationalization and footprint consolidation, reflect a common industry drive to optimize costs and improve profitability in a competitive landscape.

Comparison to Industry Standards

• The long-range plan (LRP) organic growth target of 6-8% is positioned as "200bps above market in normal market conditions," indicating an aspiration to outperform the broader industry.
• The company aims for "top-tier margins" and "industry-leading incremental margins" of 25bps per year, suggesting a goal to achieve profitability levels at the high end of its sector.
• The ~85% recurring revenue mix is a strong indicator of business model stability, which is a favorable characteristic often sought after in the life sciences tools and diagnostics industry.
• The strategic focus on AI-driven discovery and specialized diagnostics aligns with high-growth segments within the health science industry.

Stakeholder Impact

• Shareholders: Positive impact due to exceeding EPS guidance, strong revenue growth, share repurchases, and a positive future outlook.
• Employees: Potential impact from a ~10% overall headcount reduction as part of operational efficiency initiatives, though framed as increasing productivity.
• Customers: Positive impact from new AI-driven solutions (Transcribe AI, Signals Xynthetica), expanded GMP reagents, and advanced diagnostic capabilities (T1D screening).
• Creditors: Stable outlook with strong financial performance and operational improvements.

Next Steps

• Release of fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026.
• Host a conference call on February 2, 2026, at 8:00 a.m. ET to discuss Q4 and full year 2025 results.
• Prahlad Singh to present at the 44th annual J.P. Morgan Healthcare Conference on January 13, 2026.
• Continue to strengthen operationally and financially, aiming for 28.0% adjusted operating margins in 2026.
• Expand scientific and market reach, including further GMP reagents expansion and US Immunodiagnostics penetration.
• Capitalize on the potential of AI, including further deployment of Transcribe AI and development of Signals Xynthetica.
• Continue share repurchases and other capital deployment strategies.
• Work towards achieving long-range plan organic growth of 6-8% and mid-30s% gross margins.

Key Dates

Recommendation

Revvity's preliminary Q4 and full-year 2025 results indicate strong performance, with adjusted EPS expected to exceed prior guidance. The company demonstrates robust organic growth, a high recurring revenue mix, and a clear strategic roadmap focused on high-growth areas like AI, specialized diagnostics, and operational efficiencies. Significant share repurchases highlight a commitment to shareholder returns. The long-range plan targets superior organic growth and margin expansion, positioning Revvity as a compelling investment in the health science sector. The positive financial trajectory and strategic execution warrant a strong buy recommendation for seasoned investors.

Keywords

Revvity, Financial Results, Earnings, Revenue Growth, EPS, Health Science, Diagnostics, Life Sciences, Biotech, Pharmaceutical, AI, Artificial Intelligence, Immunodiagnostics, Reproductive Health, SEC Filing, Q4 2025, Full Year 2025, J.P. Morgan Healthcare Conference, Organic Growth, Adjusted Operating Margin, Share Repurchase, Capital Allocation